A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Sponsor
Eli Lilly and Company
Study ID
NCT03364309
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ixekizumab — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.

Key Dates

Start date
Apr 26, 2018
Status verified
Jun 2021
Primary completion
Jun 4, 2020
Completion
Jun 4, 2020

Study Design

Enrollment
438 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ixekizumab 80mg Q4W
    Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
  • Experimental: Ixekizumab 80mg Q2W
    Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
  • Placebo Comparator: Placebo
    Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.

Primary Outcome Measure

Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement [ Time Frame: Week 12 ]

Related Studies